Evidence map›Paper›PMID 26887815›Full record

ArticleGut2017

STAT4-associated natural killer cell tolerance following liver transplantation.

K M Jamil, T J Hydes, K S Cheent, S A Cassidy, J A Traherne, J Jayaraman, J Trowsdale, G J Alexander, A-M Little, H McFarlane and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Gut, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. STAT4 gene polymorphisms in human diseases.Frontiers in immunology · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. STAT4 Regulates the CD8Journal of immunology (Baltimore, Md. : 1950) · 2017
    Article
  16. Article
  17. Article
  18. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

K M JamilDepartment of Hepatology, Imperial College, London, UK.
T J HydesDepartment of Hepatology, Southampton University, Southampton, UK.
K S CheentDepartment of Hepatology, Imperial College, London, UK.
S A CassidyDepartment of Hepatology, Imperial College, London, UK.
J A TraherneDepartment of Pathology, University of Cambridge, Cambridge, UK.
J JayaramanDepartment of Pathology, University of Cambridge, Cambridge, UK.
J TrowsdaleDepartment of Pathology, University of Cambridge, Cambridge, UK.
G J AlexanderDepartment of Hepatology, Addenbrookes Hospital, Cambridge, UK.
A-M LittleHistocompatibility and Immunogenetics Service, Gartnavel General Hospital, Glasgow, UK.
H McFarlaneHistocompatibility and Immunogenetics Service, Gartnavel General Hospital, Glasgow, UK.
M A HeneghanInstitute of Liver Studies, Kings College Hospital London, London, UK.
M A PurbhooDepartment of Hepatology, Imperial College, London, UK.
S I KhakooDepartment of Hepatology, Imperial College, London, UK.
Imperial College London · GBUniversity of Cambridge · GBGartnavel General Hospital · GBUniversity of Southampton · GBAddenbrooke's Hospital · GBKing's College Hospital · GB

Funding

Medical Research Council MR/L016567/1Wellcome TrustWellcome Trust 092675/Z/10/Z
6 · The paper itself

Abstract

objectiveNatural killer (NK) cells are important mediators of liver inflammation in chronic liver disease. The aim of this study was to investigate why liver transplants (LTs) are not rejected by NK cells in the absence of human leukocyte antigen (HLA) matching, and to identify a tolerogenic NK cell phenotype.

designPhenotypic and functional analyses on NK cells from 54 LT recipients were performed, and comparisons made with healthy controls. Further investigation was performed using gene expression analysis and donor:recipient HLA typing.

resultsNK cells from non-HCV LT recipients were hypofunctional, with reduced expression of NKp46 (p<0.05) and NKp30 (p<0.001), reduced cytotoxicity (p<0.001) and interferon (IFN)-γ secretion (p<0.025). There was no segregation of this effect with HLA-C, and these functional changes were not observed in individuals with HCV. Microarray and RT-qPCR analysis demonstrated downregulation of STAT4 in NK cells from LT recipients (p<0.0001). Changes in the expression levels of the transcription factors Helios (p=0.06) and Hobit (p=0.07), which control NKp46 and IFNγ expression, respectively, were also detected. Hypofunctionality of NK cells was associated with impaired STAT4 phosphorylation and downregulation of the STAT4 target microRNA-155. Conversely in HCV-LT NK cell tolerance was reversed, consistent with the more aggressive outcome of LT for HCV.

conclusionsLT is associated with transcriptional and functional changes in NK cells, resulting in reduced activation. NK cell tolerance occurs upstream of major histocompatibility complex (MHC) class I mediated education, and is associated with deficient STAT4 phosphorylation. STAT4 therefore represents a potential therapeutic target to induce NK cell tolerance in liver disease.

Indexed as

Liver TransplantationAdultAgedCase-Control StudiesCross-Sectional StudiesDown-RegulationFemaleHepatitis C, ChronicHistocompatibility TestingHLA-C AntigensHumansIkaros Transcription FactorImmune ToleranceKiller Cells, NaturalLymphocyte ActivationMaleHLA-C AntigensIkaros Transcription FactorIKZF2 protein, humanMicroRNAsMIRN155 microRNA, humanNatural Cytotoxicity Triggering Receptor 1Natural Cytotoxicity Triggering Receptor 3NCR1 protein, humanNCR3 protein, humanSTAT4 protein, humanSTAT4 Transcription FactorHEPATITIS CIMMUNOLOGY IN HEPATOLOGYLIVER TRANSPLANTATIONRNA EXPRESSIONTOLERANCE

Identifiers

PMID26887815
PMCPMC5284485
OpenAlexW2283136417

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.